RAPH
Raphael Pharmaceutical Inc.
Price Chart
Latest Quote
$1.40
+0.00 (+0.00%)
Current Price
| Previous Close | $1.40 |
| Open | $0.05 |
| Day High | $0.05 |
| Day Low | $0.05 |
| Volume | 260 |
Stock Information
| Shares Outstanding | 20.18M |
| Total Debt | $37K |
| Cash Equivalents | $1K |
| Net Income | $-1.08M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $28.25M |
| EPS (TTM) | $-0.07 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $28.28M |
| Income | $-1.08M |
| Book/sh | $-0.08 |
| Cash/sh | $0.00 |
Financial Ratios
| Quick Ratio | 0.00 |
| Current Ratio | 0.00 |
Returns & Margins
| ROA | -1358.07% |
Ownership
| Insider Ownership | 46.12% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -17.07 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.40 |
| SMA50 | $1.40 |
| SMA200 | $1.11 |
| RSI | nan |
| Shares Float | 11.52M |
| Volatility | 1.85 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +0.00% |
| YTD | +0.00% |
| Year | +536.36% |
| 3 Years | -33.33% |
| 10 Years | -36.36% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $1.40 | 0 |
| 2026-06-15 | $1.40 | 0 |
| 2026-06-12 | $1.40 | 0 |
| 2026-06-11 | $1.40 | 0 |
| 2026-06-10 | $1.40 | 0 |
| 2026-06-09 | $1.40 | 0 |
| 2026-06-08 | $1.40 | 0 |
| 2026-06-05 | $1.40 | 0 |
| 2026-06-04 | $1.40 | 0 |
| 2026-06-03 | $1.40 | 0 |
| 2026-06-02 | $1.40 | 0 |
| 2026-06-01 | $1.40 | 0 |
| 2026-05-29 | $1.40 | 0 |
| 2026-05-28 | $1.40 | 0 |
| 2026-05-27 | $1.40 | 0 |
| 2026-05-26 | $1.40 | 0 |
| 2026-05-22 | $1.40 | 0 |
| 2026-05-21 | $1.40 | 0 |
| 2026-05-20 | $1.40 | 0 |
| 2026-05-19 | $1.40 | 0 |
| 2026-05-18 | $1.40 | 0 |
About Raphael Pharmaceutical Inc.
Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.
đ° Latest News
No news articles available at the moment. Check back later for updates on RAPH.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $1,509,000 | $1,332,000 | $3,317,000 | $1,629,000 |
| Rent Expense Supplemental | $3,000 | $6,000 | $9,000 | $31,000 |
| Other Income Expense | $-8,000 | $-9,000 | $-38,000 | $6,000 |
| Net Non Operating Interest Income Expense | $-2,000 | $-3,000 | $-3,000 | $5,000 |
| Total Other Finance Cost | $2,000 | $3,000 | $3,000 | $-5,000 |
| Operating Expense | $1,509,000 | $1,332,000 | $3,317,000 | $1,629,000 |
| General And Administrative Expense | $733,000 | $763,000 | $2,139,000 | $853,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Net Interest Income | $-2,000 | $-3,000 | $-3,000 | $5,000 |
| Normalized Income | $-1,511,000 | $-1,335,000 | $-3,320,000 | $-1,624,000 |
| Net Income From Continuing And Discontinued Operation | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Total Operating Income As Reported | $-1,509,000 | $-1,332,000 | $-3,317,000 | $-1,629,000 |
| Net Income Common Stockholders | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Net Income | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Net Income Including Noncontrolling Interests | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Net Income Continuous Operations | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Pretax Income | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Operating Income | $-1,509,000 | $-1,332,000 | $-3,317,000 | $-1,629,000 |
| Per Share | ||||
| Diluted EPS | $-0.08 | $-0.08 | $-0.23 | $-0.10 |
| Basic EPS | $-0.08 | $-0.08 | $-0.23 | $-0.10 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,501,000 | $-1,323,000 | $-3,279,000 | $-1,629,000 |
| Total Unusual Items | $-8,000 | $-9,000 | $-38,000 | $6,000 |
| Total Unusual Items Excluding Goodwill | $-8,000 | $-9,000 | $-38,000 | $6,000 |
| EBITDA (Bullshit earnings) | $-1,509,000 | $-1,332,000 | $-3,317,000 | $-1,629,000 |
| EBIT | $-1,509,000 | $-1,332,000 | $-3,317,000 | $-1,629,000 |
| Diluted Average Shares | $18,674,136 | $16,716,905 | $14,341,518 | $15,484,040 |
| Basic Average Shares | $18,674,136 | $16,716,905 | $14,341,518 | $15,484,040 |
| Diluted NI Availto Com Stockholders | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Gain On Sale Of Security | $-8,000 | $-9,000 | $-38,000 | $6,000 |
| Research And Development | $776,000 | $569,000 | $1,178,000 | $776,000 |
| Selling General And Administration | $733,000 | $763,000 | $2,139,000 | $853,000 |
| Other Gand A | $730,000 | $757,000 | $440,000 | $822,000 |
| Rent And Landing Fees | $3,000 | $6,000 | $9,000 | $31,000 |
| Salaries And Wages | - | $0 | $1,690,000 | $0 |
| Reconciled Depreciation | - | - | $0 | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-742,000 | $107,000 | $106,000 | $128,000 |
| Total Assets | $27,000 | $239,000 | $333,000 | $422,000 |
| Total Non Current Assets | $2,000 | $2,000 | $2,000 | $0 |
| Current Assets | $25,000 | $237,000 | $331,000 | $422,000 |
| Prepaid Assets | $4,000 | $0 | $5,000 | $177,000 |
| Receivables | $2,000 | $7,000 | $38,000 | $92,000 |
| Other Receivables | $2,000 | $7,000 | $38,000 | $92,000 |
| Cash Cash Equivalents And Short Term Investments | $19,000 | $230,000 | $288,000 | $153,000 |
| Cash And Cash Equivalents | $19,000 | $230,000 | $288,000 | $153,000 |
| Debt | ||||
| Net Debt | $22,000 | - | - | - |
| Total Debt | $41,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $41,000 | - | - | - |
| Current Debt | $41,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $769,000 | $132,000 | $227,000 | $294,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $769,000 | $132,000 | $227,000 | $294,000 |
| Payables And Accrued Expenses | $728,000 | $132,000 | $227,000 | $294,000 |
| Payables | $353,000 | $107,000 | $75,000 | $129,000 |
| Accounts Payable | $125,000 | $69,000 | $72,000 | $107,000 |
| Equity | ||||
| Common Stock Equity | $-742,000 | $107,000 | $106,000 | $128,000 |
| Total Equity Gross Minority Interest | $-742,000 | $107,000 | $106,000 | $128,000 |
| Stockholders Equity | $-742,000 | $107,000 | $106,000 | $128,000 |
| Retained Earnings | $-8,889,000 | $-7,370,000 | $-6,026,000 | $-2,667,000 |
| Other | ||||
| Ordinary Shares Number | $18,701,418 | $18,502,918 | $15,624,040 | $15,484,040 |
| Share Issued | $18,701,418 | $18,502,918 | $15,624,040 | $15,484,040 |
| Tangible Book Value | $-742,000 | $107,000 | $106,000 | $128,000 |
| Invested Capital | $-701,000 | $107,000 | $106,000 | $128,000 |
| Working Capital | $-744,000 | $105,000 | $104,000 | $128,000 |
| Total Capitalization | $-742,000 | $107,000 | $106,000 | $128,000 |
| Treasury Stock | $0 | $100,000 | - | - |
| Additional Paid In Capital | $7,960,000 | $7,392,000 | $5,975,000 | $2,665,000 |
| Capital Stock | $187,000 | $185,000 | $157,000 | $130,000 |
| Common Stock | $187,000 | $185,000 | $157,000 | $130,000 |
| Current Accrued Expenses | $375,000 | $25,000 | $152,000 | $165,000 |
| Dueto Related Parties Current | $228,000 | $38,000 | $3,000 | $22,000 |
| Net PPE | $2,000 | $2,000 | $2,000 | $0 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-532,000 | $-1,203,000 | $-761,000 | $-1,418,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-532,000 | $-1,203,000 | $-759,000 | $-1,418,000 |
| Cash Flow From Continuing Operating Activities | $-532,000 | $-1,203,000 | $-759,000 | $-1,418,000 |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $0 | $-2,000 | $0 |
| Cash Flow From Continuing Investing Activities | $0 | $0 | $-2,000 | $0 |
| Capital Expenditure | - | - | $-2,000 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $280,000 | $1,145,000 | $896,000 | $1,289,000 |
| Financing Cash Flow | $321,000 | $1,145,000 | $896,000 | $1,476,000 |
| Cash Flow From Continuing Financing Activities | $321,000 | $1,145,000 | $896,000 | $1,476,000 |
| Net Common Stock Issuance | $280,000 | $1,145,000 | $896,000 | $1,289,000 |
| Common Stock Issuance | $280,000 | $1,145,000 | $896,000 | $1,289,000 |
| Net Other Financing Charges | - | - | - | $13,000 |
| Other | ||||
| Issuance Of Debt | $41,000 | $0 | $0 | $174,000 |
| End Cash Position | $19,000 | $230,000 | $288,000 | $153,000 |
| Beginning Cash Position | $230,000 | $288,000 | $153,000 | $95,000 |
| Changes In Cash | $-211,000 | $-58,000 | $135,000 | $58,000 |
| Net Issuance Payments Of Debt | $41,000 | $0 | $0 | $174,000 |
| Net Short Term Debt Issuance | $41,000 | $0 | $0 | $174,000 |
| Short Term Debt Issuance | $41,000 | $0 | $0 | $174,000 |
| Net PPE Purchase And Sale | $0 | $0 | $-2,000 | $0 |
| Purchase Of PPE | $0 | $0 | $-2,000 | $0 |
| Change In Working Capital | $597,000 | $-59,000 | $309,000 | $206,000 |
| Change In Other Working Capital | $190,000 | $35,000 | $-19,000 | $13,000 |
| Change In Other Current Assets | $1,000 | $36,000 | $226,000 | $-41,000 |
| Change In Payables And Accrued Expense | $406,000 | $-130,000 | $102,000 | $234,000 |
| Change In Payable | $406,000 | $-130,000 | $102,000 | $234,000 |
| Change In Account Payable | $406,000 | $-130,000 | $102,000 | $234,000 |
| Stock Based Compensation | $390,000 | $200,000 | $2,290,000 | $0 |
| Net Income From Continuing Operations | $-1,519,000 | $-1,344,000 | $-3,358,000 | $-1,624,000 |
| Depreciation Amortization Depletion | - | - | $0 | - |
| Depreciation And Amortization | - | - | $0 | - |
| Depreciation | - | - | $0 | - |
Fetched: 2026-02-02